RetinaCME
EXPERT REVIEWCMEABO MOC

Exercising Trial and Error to Improve the Treatment of Diabetic Retinopathy

Author(s)/Faculty: W. Lloyd Clark, MD; Dilsher S. Dhoot, MD; Charles C. Wykoff, MD, PhD
Release Date: 8/28/2020Expiration Date: 8/27/2021
Credit Type: CME / ABO MOCNumber of Credits: 0.75
Content Type: LectureProvider:
Sub-analysis of pinnacle trials utilizing anti–vascular endothelial growth factor (VEGF) therapies for the treatment of diabetic macular edema (DME) has demonstrated the efficacy of these agents in reducing the severity of diabetic retinopathy (DR) and the potential to reverse DR progression. Subsequent studies have further evaluated the clinical efficacy of anti-VEGF therapies in the management of DR without DME, providing further support for early therapy intervention to slow disease progression. Within this educational activity, experts in the field will assess early treatment as well as new injection protocols for their ability to improve dosing and management of patients with DR, evaluate the efficacy of anti-VEGF therapy in patients with proliferative versus non-proliferative DR, and compare current therapeutic regimens for their ability to achieve regression of DR.